Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 9/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11253060 | 0.91 | NOTUM (0.43) | MAPK10MAPK9MAPK8NOTUM | |
| SCHEMBL11252379 | 0.88 | FLT3 (0.50) | MAPTFLT3 | |
| SCHEMBL15022321 | 0.88 | CYP3A4 (0.39) | MAPK10MAPK9MAPTLMNAFLT3 | |
| SCHEMBL15022094 | 0.84 | HDAC8 (0.44) | MAPK10MAPK9MAPTFLT3MAPKAPK2 | |
| SCHEMBL15022969 | 0.79 | MAPT (0.34) | MAPK10MAPK9MAPK8MAPTFLT3 | |
| SCHEMBL7045196 | 0.78 | SMN1; SMN2 (0.43) | LMNA | |
| SCHEMBL28332948 | 0.78 | MAPK9 (0.37) | MAPK10MAPK9MAPK8MAPTFLT3 | |
| SCHEMBL9007470 | 0.73 | GAA (0.41) | MAPTLMNABCHENOTUMTDP1 | |
| SCHEMBL17457966 | 0.73 | MEN1 (0.37) | MAPK10MAPK9MAPK8MAPTLMNA | |
| Bicarbonate SCHEMBL9488633 | 0.72 | SMN1; SMN2 (0.50) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | MAPK10 650/4885MAPK9 616/4885MAPK8 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.